Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Fig. 3

Echocardiographic assessment of diastolic function. Cardiac function was evaluated in 11 week old mice prior to treatment (Pre) and again at 15 weeks of age at the end of treatment. Bar graphs show significant improvements in diastolic parameters in DbE compared to DbC including the a Tissue Doppler derived E′/A′ ratio indicating improved septal wall motion and b E/E′ ratio indicating improved LV filling pressure. *P < 0.05 compared to CKC at the same time point; P < 0.05 compared to DbC at the same time point

Back to article page